TERZO - A multicentre, open-label, Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (SBI-0145-304) (SBI-0145-304 (TERZO))

Principal Investigator

Dr Graham Collins

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1010625